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REVIEW
Management of acute coronary syndromes 
with fondaparinux
Abstract: Fondaparinux is the ﬁ  rst selective inhibitor of the coagulation factor Xa which 
is commercially avaliable for clinical use. It has been approved for the prevention of venous 
thromboembolism in patients undergoing orthopedic surgery and for the initial therapy of venous 
thromboembolism. In randomized clinical trials the value of fondaparinux in the treatment of 
ST-elevation myocardial infarction (STEMI) has been investigated. The PENTALYSE study 
showed that fondaparinux was at least as effective and safe as unfractionated heparin in 333 
patients with STEMI undergoing ﬁ  brinolysis with t-PA. In the recent large OASIS-6 trial with 
12,092 patients the treatment with 2.5 mg fondaparinux daily signiﬁ  cantly reduced death and 
reinfarctions until day 30 compared with guideline recommended usual care and compared 
with unfractionated heparin (9.7% vs 11.2%, p = 0.008) without increasing major bleedings 
(1.0% vs 1.3%, p = 0.13). This advantage was predominantly seen in the subgroups of patients 
with ﬁ  brinolysis and without early reperfusion therapy. However, in the subgroup of primary 
percutaneous coronary interventions (PCIs) no clinical beneﬁ  t of fondaparinux was found, but 
there were more catheter thrombosis and acute thrombotic complications. In summary, fonda-
parinux is a new antithrombin that is an efﬁ  cient, safe, and easy to use in treatment for STEMI 
patients, particularly those not undergoing primary PCI.
Keywords: selective factor Xa inhibition, fondaparinux, acute ST-elevation myocardial infarc-
tion, antithrombin therapy
Introduction
Antithrombin therapy in ST-elevation myocardial infarction
The pathophysiological mechanism of acute ST-elevation myocardial infarction 
(STEMI) is the rupture of a vulnerable or high-risk plaque and exposition of its con-
tents to the passing bloodstream, resulting in activation of the coagulation cascade, 
which ultimately results in the deposition of ﬁ  brin strands. In addition, platelets are 
activated and aggregate. The cornerstone of acute management for STEMI is early 
reperfusion therapy with primary percutaneous coronary intervention (PCI) or ﬁ  bri-
nolysis. Due to the pathophysiological mechanisms there is a rationale for adjunctive 
medical therapy with anticoagulants to inhibit the coagulation cascade in patients 
with STEMI. In addition to establishing and maintaining patency of the infarct-related 
artery, antithrombins are given in STEMI patients for prevention of left ventricular 
thrombus, cerebral embolization, deep-vein thrombosis, and pulmonary embolism 
(Antman et al 2004).
Unfractionated heparin
The traditional anticoagulant in treatment of STEMI patients is unfractionated 
heparin. Heparins are naturally occurring glycosaminoglycans acting as cofactors 
of endogenous inhibitors of coagulation (antithrombin, heparin cofactor II). The 
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heparin effect has multiple targets in the coagulation cas-
cade (Freedman 1992). In clinical practice unfractionated 
heparin has been used in patients with myocardial infarction 
for over 40 years.
The ACC/AHA guidelines recommend unfractionated 
heparin in STEMI patients undergoing percutaneous or surgi-
cal revascularization and in patients undergoing reperfusion 
therapy with ﬁ  brin-speciﬁ  c thrombolytic agents (Class I 
recommendation). In reperfusion therapy with non-speciﬁ  c 
ﬁ  brinolytic agents, which themselves produce a systemic 
coagulopathy, unfractionated heparin is recommended in 
patients at high risk of systemic emboli, and patients with 
large myocardial infarction or known left ventricular throm-
bus (Class I recommendation) (Antman et al 2004). 
In patients treated with ﬁ  brin speciﬁ  c ﬁ  brinolytics such 
as t-PA, reteplase or tenecteplase effective anticoagulation 
(aPTT 2-3 times control) is associated with an improved 
patency rate of the infarct vessel and a reduction in the rate 
of reinfarctions.
However, the current role of unfractionated heparin 
in the treatment of STEMI patients is controversial and 
the search for better alternatives in the anticoagulative 
treatment began years ago. Major bleedings, especially 
hemorrhagic stroke, are the most important complications 
of antithrombin therapy. The correct dose of unfractionated 
heparin to achieve beneﬁ  cial effects and avoid bleeding 
complications depends on other adjunctive treatments of 
STEMI patients, body weight, and concomitant diseases. 
The anticoagulant effect of unfractionated heparin can be 
measured by the activated clotting time (ACT) in the set-
ting of primary angioplasty or by the partial thromboplastin 
time (PTT) in thrombolysis patients. However, a limita-
tion in predictable bioavailability and maintenance of the 
therapeutic range of unfractionated heparin has been criti-
cized by different authors (Gurﬁ  nkel et al 1998). A further 
complication of treatment with unfractionated heparin is 
heparin-induced thrombocytopenia (HIT). The incidence of 
HIT in therapy with unfractionated heparin is 3% and it is 
associated with a substantial risk of prothrombotic events 
and a worse prognosis. The ACC/AHA guidelines there-
fore recommend daily platelet counts in patients receiving 
unfractionated heparin (Antman et al 2004).
Low-molecular-weight heparins
Low-molecular-weight heparins have the pharmaco-
logical advantages of better bioavailability and minimal 
protein binding compared with unfractionated heparin, 
and they are associated with a lower rate of heparin-in-
duced thrombocytopenia. Different recent studies investi-
gated the value of low-molecular-weight heparins in STEMI 
and ﬁ  brinolysis. By far best studied low-molecular-weight 
heparin is enoxaparin.
In the ASSENT-3 and ASSENT-3 PLUS trials a superior-
ity of enoxaparin compared with unfractionated heparin was 
found in patients receiving tenecteplase for the combined end 
point of efﬁ  ciacy and safety (a composite of 30-day mortality, 
reinfarction, refractory ischemia, and bleeding). An excess 
of intracranial hemorrhage was observed in elderly women 
>75 years (Armstrong et al 2006). 
The ExTRACT-TIMI 25 trial randomly assigned 20506 
patients with STEMI who were scheduled to undergo ﬁ  bri-
nolysis to receive enoxaparin throughout hospitalization or 
weight-based unfractionated heparin for at least 48 hours. The 
enoxaparin dosing strategy was adjusted according to patient`s 
age and renal function. A reduced dosage for patients at least 
75 years of age or with an estimated creatinine clearance of 
less than 30 mL/minute omitted the intravenous bolus and 
reduced the s.c. dose to 75%. Unfractionated heparin was to 
be administered beginning with an intravenous bolus of 60 
U/kg body weight (maximum 4000 U, the bolus was to be 
omitted for patients who received open-label unfractionated 
heparin within three hours before randomization), followed by 
an infusion of 12 U/kg/hour (maximum 1000 U/hour). 
The ExTRACT-TIMI 25 investigators found a superior-
ity of enoxaparin compared with unfractionated heparin in 
STEMI patients undergoing thrombolysis for death and rein-
farctions after 30 days (12.0% vs 9.9%, p < 0.001); however 
more major bleedings were observed in the enoxaparin group 
(1.4 vs 2.1%, p < 0.001) (Antman et al 2006).
Despite the pharmacological advantages of low-mo-
lecular-weight heparins compared with unfractionated 
heparin – better bioavailability, minimal protein binding, and 
lower rate of heparin-induced thrombocytopenia – therapy 
with low-molecular-weight heparins still has some prob-
lems. 
The risk of bleedings is the major problem of this treat-
ment. Low-molecular weight heparins have to be dosed 
carefully in the elderly and in patients with renal function 
to avoid cumulation and major bleedings. In the bleeding 
situation an antagonism with protamin is not as helpful as 
with unfractionated heparin. Because low-molecular-weight 
heparins have a cross-reactivity with HIT antibodies, they 
should not be used in HIT patients. 
For these reasons new antithrombins were sought with a 
speciﬁ  c mode of action, an easy and safe way of use, and high 
efﬁ  cacy in the treatment of acute coronary syndromes. Vascular Health and Risk Management 2007:3(3) 323
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Thrombin inhibitors
Anticoagulants may inhibit the coagulation cascade at mul-
tiple positions (as heparins) or selectively. In the search for 
an optimal anticoagulant, selective inhibition of coagulation 
factors is an attractive strategy to produce predictable anti-
coagulant response (Bauer 2006). 
The ﬁ  rst selective inhibitors of a speciﬁ  c coagulation 
factor were the recombinant hirudins, which target thrombin 
(= factor II). Hirudins are direct thrombin inhibitors, which 
inhibit thrombin by directly binding to speciﬁ  c surface 
binding sites. Hirudins have been shown to have a rather 
narrow therapeutic window, limiting their use in the general 
population.
It was hypothesized that selective inhibitors of coagula-
tion factors located further upstream in the coagulation path-
way might be safer with respect to bleeding by not inhibiting 
thrombin activity directly. Factor Xa has been identiﬁ  ed as 
a potential target for the design of new anticoagulants, as 
selective inhibitors of factor Xa would effectively block 
coagulation (Bauer 2006). 
Fondaparinux is the ﬁ  rst of the selective Xa inhibitors 
with clinical importance. It is an indirect factor Xa inhibitor 
(Figure 1). It is a pentasaccharide designed speciﬁ  cally to 
bind to plasma antithrombin. This binding induces a confor-
mational change in antithrombin which increases the afﬁ  nity 
of antithrombin for factor Xa, potentiating the natural inhibi-
tory effect of antithrombin against factor Xa. 
The selective action of fondaparinux towards factor Xa 
contrasts with the action of unfractionated heparin, which has 
activity against a number of coagulation factors and equipo-
tent activitity against factor IIa and Xa, and it contrasts with 
low-molecular-weight heparin which is also non-speciﬁ  c 
and has more activity against factor Xa than against factor 
IIa (Bauer 2006). 
Intrinsic
pathway
Extrinsic
pathway
Antithrombin
THROMBIN
Fibrin clot Fibrinogen
Fondaparinux II IIa
Figure 1 Mode of action of fondaparinux.Vascular Health and Risk Management 2007:3(3) 324
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Pharmacological properties 
of fondaparinux
Fondaparinux contrasts with the previously described pharma-
cological characteristics of heparins (low bioavailability in un-
fractionated heparins, heterogenous structure and multiple targets 
in the coagulation pathway in all heparins, and heparin-induced 
thrombocytopenia especially in unfractionated heparins). 
The main pharmacological properties of fondaparinux are 
listed in Table 1. Due to the unchanged elimination in urine 
the dose must be reduced in elderly patients, and patients 
with impaired renal function.
Following the product information of fondaparinux 
sodium (Arixtra®, GlaxoSmithKline, NC, USA), therapy 
is contraindicated in patients with severe renal impairment 
(creatinine clearance <30 mL/minute). 
In patients with body weight <50 kg prophylactic 
fondaparinux therapy in surgery patients is contraindicated 
due to higher bleeding complications. In the therapy of deep 
vein thrombosis and pulmonary embolism a weight-depend-
ing dosage is recommended (5 mg daily in patients with 
body weight <50 kg, 7.5 mg in patients with 50–100 kg, 
10 mg in patients with >100 kg). It is recommended to use 
fondaparinux with caution in elderly patients. 
In patients with active major bleeding or bacterial endo-
carditis, fondaparinux is contraindicated. Therapy should 
be used with care in patients with a bleeding diathesis, un-
controlled arterial hypertension or history of gastrointestinal 
ulceration, diabetic retinopathy, and hemorrhage. 
In the large clinical studies on fondaparinux in acute coro-
nary syndromes (OASIS 5 and 6), patients with creatinine 
levels greater than 3.0 mg/dL, contraindications to anticoagu-
lation, including high risk of bleeding, recent hemorrhagic 
stroke, and receiving oral anticoagulants were excluded. 
Fondaparinux – clinical studies
Studies in prevention and treatment 
of venous thromboembolism
In four multicenter randomized trials (EPHESUS, PEN-
TATHLON, PENTHIFRA, PENTAMAKS) the thrombo-
prophylactic efﬁ  cacy and safety of fondaparinux in patients 
undergoing orthopedic surgery was evaluated. 
A meta-analysis of the four studies showed that 
fondaparinux is more effective than enoxaparin in prevent-
ing venous thrombosis in patients undergoing orthopedic 
surgery (Figure 2). The incidence of pulmonary embolism 
did not differ between fondaparinux and enoxaparin. The 
incidence of major bleedings under fondaparinux was signiﬁ  -
cantly lower when the ﬁ  rst injection was given at 6 hours or 
more after skin closure compared with patients with earlier 
fondaparinux injection after skin closure with comparable 
incidence of thromboembolism (Bauer 2006). 
The MATISSE-DVT and MATISSE-PE trials showed 
that initial therapy of deep-vein thrombosis or pulmonary 
embolism with fondaparinux was at least as efﬁ  cacious 
and safe as low-molecular-weight heparin or intravenous 
unfractionated heparin (Bauersachs 2005).
After these studies were published, fondaparinux was 
FDA approved for prevention of venous thromboembolism 
following hip surgery, total knee replacement, and major 
abdominal surgery and was also FDA approved for the 
initial treatment of patients with deep-vein thrombosis and 
pulmonary embolism.
Studies in patients with acute coronary 
syndromes without ST elevations
PENTUA
In PENTUA four different doses of fondaparinux (2.5 mg, 
4 mg, 8 mg, 12 mg once daily) and enoxaparin (1 mg twice 
daily) were compared, both given for 3–7 days in 1138 
patients with acute coronary syndromes without ST segment 
elevations. There was no dose-dependent effect observed for 
ischemic events until day 9 or severe bleeding complica-
tions. The lowest event rates for the combination of death, 
myocardial infarction, and recurrrent ischemia were observed 
in the 2.5 mg (30%) fondaparinux group, which was signiﬁ  -
cantly lower than in the enoxaparin group (40.2%, p < 0.05). 
Therefore this dose regimen was selected for further studies 
in patients with acute coronary syndromes.
Table 1 Main pharmacological properties of fondaparinux
Source Synthetic
Structure Homogenic
Molecular weight  1728 Dalton
Target Speciﬁ  c factor Xa
Protein binding in plasma  Thrombin only
Administration  Intravenous or subcutaneous 
 Once  daily
Time to peak concentrationn  2 hours
Plasma half life  17 hours
Bioavailibility 100%
Hepatic metabolism  No
Elimination  Unchanged in urine
Monitoring of coagulation parameters  No
Heparin-induced thrombocytopenia  NoVascular Health and Risk Management 2007:3(3) 325
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OASIS 5
In the OASIS-5 (Fifth Organization to Assess Strategies in 
Acute Ischemic Syndromes) trial, 20,078 patients with acute 
coronary syndromes without ST elevation were randomized 
to either fondaparinux (2.5 mg daily) or enoxaparin (1 mg/kg 
twice daily) for a mean of 6 days (Yusuf et al 2006). The 
primary outcome at 9 days (death, myocardial infarction, or 
refractory ischemia) was similar in the two groups (5.9% vs 
5.8%). After 30 days (8.1% vs 8.8%) and 180 days (12.1% 
vs 13.1%) a non-signiﬁ  cant trend towards a lower value was 
found in the fondaparinux group. The rate of major bleedings at 
day 9 was signiﬁ  cantly lower in the fondaparinux group (2.1% 
vs 4.0%). Fondaparinux was associated with a signiﬁ  cantly 
reduced number of deaths at 30 days (2.9% vs 3.5%, p = 0.022) 
and at 180 days (5.6% vs 6.3%, p = 0.037). 
In summary, the OASIS-5 trial showed that fondaparinux 
in acute coronary syndromes without ST elevations is com-
parable with enoxaparin in preventing ischemic events, is 
associated with fewer bleedings than enoxaparin, and is 
associated with a lower mid-term mortality. 
Studies in patients with PCI
In the ASPIRE trial 350 patients undergoing elective or 
urgent PCI were randomized to receive unfractionated 
heparin, 2.5 mg fondaparinux, or 5 mg fondaparinux intra-
venously. Fondaparinux was comparable to unfractionated 
heparin for clinical safety and efﬁ  cacy outcomes: the inci-
dence of bleeding was 7.7% in the heparin group and 6.4% 
in the combined fondaparinux group (with fewer bleedings 
with 2.5 mg than 5 mg fondaparinux); the composite ef-
ﬁ  cacy outcome (mortality, myocardial infarction, urgent 
revascularization, bailout GPIIb/IIIa antagonist) occurred 
in 6.0% both in the heparin group and in the fondaparinux 
group (Mehta et al 2005).
Fondaparinux better Enoxaparin better
Ephesus
N = 1817
Pentathlon 2000
N = 1817
Penthifra
N = 1250
Pentamaks
N = 724
Overall Odds
Reduction
Overall odds reduction for proximal DVT = 57.4%
[Cl: 72.3 − 35.6]; p = 10−6
P = 0.000000000000000001
−100 60 04 0 20 100 80 −20 −40 −60 −80
% odds reduction
55.3%
63.1%
61.6%
28.1%
58.5%
Figure 2  Meta-analysis of fondaparinux versus enoxaparin in prevention of deep venous thrombosis prevention in randomized clinical trials. Compiled from data of Turpie 
et al (2002)
Abbreviations: DVT, deep vein thrombosis.
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Studies in patients with STEMI
The PENTALYSE study
In 2001, ﬁ  rst results on fondaparinux (factor Xa inhibi-
tor ORG31540/SR9017A) in patients with STEMI were 
published by the PENTALYSE study group. In this trial 
333 patients with STEMI of less than 6 hours’ duration 
were treated with aspirin and alteplase and randomized to 
unfractionated heparin (given intravenously 48–72 hours) 
or to a low (4 mg), medium (8 mg), or high (12 mg) dose of 
fondaparinux (given daily for 5–7 days, ﬁ  rst intravenously, 
then subcutaneously). Coronary angiography was performed 
at 90 minutes after the start of ﬁ  brinolysis and on days 5–7. 
Fondaparinux given together with alteplase was as effective 
as unfractionated heparin in restoring coronary artery patency 
and was as safe as unfractionated heparin (identical primary 
safety end point of intracranial hemorrhage and need for 
blood transfusion) (Coussement et al 2001). Fondaparinux 
was associated with a trend towards a reduction in the rate 
of reocclussions between days 1 and 5 (Figure 3).
OASIS-6 
In the randomized, double-blind OASIS-6 trial 12,092 pa-
tients with STEMI presenting within 24 hours after onset of 
symptoms were included. Exclusion criteria were contrain-
dications to anticoagulation, including those at high risk of 
bleeding, receiving oral anticoagulants, or with creatinine 
>3 mmol/L. Randomization was stratiﬁ  ed by indication for 
the use of unfractionated heparin according to the current 
guidelines as judged by the investigators: stratum 1: no in-
dication for heparin; stratum 2: indication for unfractionated 
heparin (eg, ﬁ  brin-speciﬁ  c ﬁ  brinolysis, primary PCI, ﬁ  brino-
lysis but eligible for antithrombotics). In stratum 1 blinded 
fondaparinux (2.5 mg daily for up to 8 days) or placebo was 
given; in stratum 2 blinded fondaparinux (2.5 mg daily for up 
to 8 days) or unfractionated heparin (intravenous for 24–48 
hours) was given (Yusuf et al 2006).
The primary end point of a composite of death or reinfarc-
tion at 30 days was signiﬁ  cantly reduced by fondaparinux 
(9.7% fondaparinux group vs 11.2% control group, hazard ra-
tio (HR) 0.86, conﬁ  dence interval [CI] 0.77–0.96; p = 0.008) 
(Figure 4). These beneﬁ  ts were also observed after 9 days 
and at the ﬁ  nal follow-up (3–6 months) and were not heter-
ogenous in the two strata. 
However, in patients with primary PCI no beneﬁ  t by 
fondaparinux was found. If primary PCI was performed 
without addition of a small amount of unfractionated hepa-
rin, a higher rate of coronary complications – mainly due to 
guiding catheter thrombosis – was found (Table 2), without 
a signiﬁ  cant increase in myocardial infarction or death or a 
negation of the overall beneﬁ  ts. In the 496 patients receiv-
ing heparin prior to primary PCI, no differences in catheter 
thrombosis (0 vs 2), coronary complications (24 vs 24), 
and bleeding complications (1 vs 4) between heparin and 
fondaparinunx were observed.
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Figure 3  Incidence of worsening of TIMI ﬂ  ow grade in the infarct vessel between 90 minutes and day 5 in the PENTALYSE trial.
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In patients with ﬁ  brinolysis and in patients without reper-
fusion therapy, fondaparinux was superior to unfractionated 
heparin (Figure 5). 
In the fondaparinux group a non-signiﬁ  cant trend of fewer 
severe bleedings and a signiﬁ  cantly lower rate of cardiac 
tamponade was found (Table 3). Interestingly the incidence 
of bleeding complications in stratum 1 with fondaparinux 
was lower than placebo (1.0% vs 1.6%).  
In summary, the OASIS-6 trial showed a moderate but sig-
niﬁ  cant reduction in mortality and reinfarctions by fondaparinux 
compared with usual care and unfractionated heparin, without 
increasing bleeding or hemorrhagic stroke in STEMI patients. 
In patients undergoing primary PCI this beneﬁ  t was not 
found and the patients with fondaparinux showed a higher rate 
of guiding catheter thrombosis and coronary complications 
during PCI, if PCI was performed without unfractionated 
heparin. Among the 496 patients who received heparin prior 
to primary PCI, no differences in the rate of death and myo-
cardial infarction, coronary complications, catheter thrombus, 
and severe bleedings were observed. These data indicate that 
the additional use of heparin with fondaparinux during PCI is 
safe and avoids thrombotic complications. 
Summary
After the OASIS-5 trial had shown that fondaparinux is an ef-
ﬁ  cient and safe anticoagulant in the treatment of acute coronary 
syndromes without ST elevations, the OASIS-6 trial demon-
strated a reduction in mortality and reinfarctions by fondaparinux 
compared with usual care and unfractionated heparin in more 
than 10,000 patients with STEMI. Treatment of STEMI patients 
with fondaparinux was safe and not associated with an increase 
in bleedings or hemorrhagic strokes.
Table 2 Outcomes/complications at 30 days in patients undergoing PCI in the OASIS-6 trial
  PCI - UFH group   PCI – fondaparinux   P value
  (1898 patients)  group(1890 patients)
Death or myocardial infarction  93  114  ns
Guiding catheter thrombosis  0  22  <0.001
Coronary complicationsa   225  270  0.04
aCoronary complications were: abrupt coronary artery closure, new angiographic thrombus, catheter thrombus, no reﬂ  ow, dissection, perforation. 
Abbreviations: PCI, percutaneous coronary intervention; UFH, unfractionated heparin.
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Figure 4 Incidence of the combined endpoint of death and myocardial infaction at different times points after randomization in the OASIS-6 trial.
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However, some points and possible disadvantages of 
fondaparinux have to be discussed. 
For primary PCI in STEMI patients, the actual data of the 
OASIS-6 trial suggest that at least during the intervention, un-
fractionated heparin is necessary in addition to fondaparinux 
to avoid catheter thrombosis and ischemic complications. 
However, in the ASPIRE trial performed on patients with 
elective PCI, no difference in coronary complications was 
observed between heparin and fondaparinux (Metha 2005). 
The data of the OASIS trials suggest that a periprocedural 
combined use of unfractionated heparin and fondaparinux is 
safe; nonetheless, further prospective evaluation seems to be 
required analyzing fondaparinux/unfractionated heparin and 
the periprocedural antithrombotic strategy in PCI patients. 
The reasons for the insufﬁ  cient antithrombotic effect of 
fondaparinux in foreign materials such as catheters should 
be evaluated. Based on available data, fondaparinux should 
be used in primary PCI with the addition of unfractionated 
heparin.
Compared with the large clinical experience, which phy-
sicians have achieved with respect to heparin treatment in the 
past years, little is known about treatment with fondaparinux 
in clinical practice. No data exist on fondaparinux treatment 
in patients, who escape the inclusion criteria of randomized 
trials. However, the OASIS-6 trial included a wide variety of 
patients, assuring the applicability of the results to a general 
population of STEMI patients.
No data are available that compare fondaparinux and low-
molecular-weight heparins in the treatment of STEMI. Both 
the PENTALYSE and OASIS-6 trials compared fondaparinux 
and unfractionated heparin. The OASIS-5 trial compared 
fondaparinux and enoxaparin, but was performed in acute 
coronary syndromes without ST elevations. With respect to 
the recent investigations of low-molecular-weight heparins 
in STEMI patients (ASSENT-3, ExTRACT TIMI 25), a 
comparison of fondaparinux and enoxaparin seems to be 
warranted. 
In OASIS 6 in both groups only ~2% of the patients 
received GP IIb/IIIa-antagonists (~16% thienopyridine re-
spectively) within 7 days of randomization (during the hos-
pital course after randomization ~16% IIb/IIIa-antagonists 
and ~58% thienopyridine). Further studies investigating the 
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Figure 5 Combined endpoint according to the randomization strata in the OASIS-6 study.
Abbreviations: MI, myocardial infarction; PCI, percutaneous coronary intervention. 
Table 3 Major bleeding complications until day 9 in the OASIS-6 
trial
  Placebo or UFH  Fondaparinux  P value
All cases  2.1%  1.8%  0.14
Stratum 1  2.0%  1.4%  0.07
Stratum 2  2.3%  2.1%  0.7
- No PCI  3.2%  2.2%  0.09
- PCI  1.7%  2.2%  0.27
Abbreviations: PCI, percutaneous coronary intervention; UFH, unfractionated 
heparin.Vascular Health and Risk Management 2007:3(3) 329
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efﬁ  cacy and safety of fondaparinux in patients receiving high-
dose antithrombotic therapy with GP IIb/IIIa-antagonists and 
high-dose clopidogrel therefore seem warranted.  
In the bleeding situation there is no known antidote for 
fondaparinux.
On the other hand, the actual studies present fondaparinux 
as a safe and efﬁ  cient new antithrombotic agent in the treat-
ment of acute coronary syndromes. A major advantage of 
fondaparinux is its ease of use. A single daily subcutaneous 
administration of 2.5 mg fondaparinux provides a stable and 
predictable anti-coagulation without the need for laboratory 
control of coagulation parameters. In addition it is not associ-
ated with the risk of heparin associated thrombocytopenia. 
Therefore it can be used in a wide range of patients and set-
tings. The data of the OASIS-6 trial suggest that selective 
factor Xa inhibition with fondaparinux is an attractive, easy 
to use, and therefore widely applicable new antithrombotic 
strategy in the treatment of STEMI. 
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